

Results of the NOGGO/GCIG/ENGOT-ov22 survey in 2101 patients

ENGOT
European Network of
Gynecological Oncology Trial Groups

GYNECOLOGIC
CANCER INTERGROUP

NOGGO
c.v.

Nederlandse Vereniging voor Geneeskunde
En Gynaecologische Oncologie n.v.

What are the expectations of patients with ovarian cancer to a maintenance therapy?

Authors:

I. Rohr¹, M. Keller², R. Chakerov³, G. Oskay-Özcelik³, R. Richter³, M. Heinrich⁴, C. Taskiran⁵, F. Joly⁶, P. Wolfrum-Ristau⁷, A. Gornjec⁸, I. Vergote⁹, P. Achimas¹⁰, D. Lorusso¹¹, J. Maenpää¹², J. Sehouli¹³

Participating countries:

Austria, Belgium, Italy, Romania, Slovenia, France, Germany, Turkey, Finland, Spain (A-AGO, BGOG, MITO, GINECO, NOGGO, TRSGO, NSGO)

„The NOGGO Expression Series“

NOGGO
ENGOT
GYNECOLOGIC
CANCER INTERGROUP

- **Expression I:** Breast cancer patients' expectations in respect of the physician–patient relationship and treatment management (n= 617)
- **Expression II:** What do primary and recurrent ovarian cancer (OC) patients expect from their Doctors and therapy management? (only in Germany) (n= 676)
- **Expression III/ ENGOT-ov4:** What do primary and recurrent ovarian cancer (OC) patients expect from their Doctors and therapy management? (n= 1830)
- **Expression IV/ENGOT-ov22: What do primary and recurrent ovarian cancer patients expect from maintenance therapy? (n= 2101)**
- **Expression V:** Berlin survey about expectations and preferences of ovarian, fallopian tube or peritoneal cancer patients with and without migration www.expression5.net (n= 688)
- **Expression VI: Carolin meets Hanna - Holistic Analysis of longterm survivors with ovarian cancer n= 78 (ongoing)**

Aims and design

The current and future clinical reality:


Maintenance therapy in ovarian cancer has a crucial role in the clinical day and in research (eg. PARP inhibitors, antiangiogenesis, checkpoint inhibitors) but have

- different side effects
- different administration forms
- different schedules
- different comparators in the trials



Results

NOGGO
ENGOT
GYNECOLOGIC
CANCER INTERGROUP



1954 evaluable participants


Results

	n= 1954 participants	All
Age	18-50 years	19.5 %
	51-70 years	62.0 %
	71-90 years	18.5 %
Stage of disease	Primary ovarian cancer	49.6 %
	Relapsed ovarian cancer	36.3 %
	Unknown	6.9 %
FIGO Stage at primary disease	I-II	14.3 %
	III-IV	43.7 %
	Unknown	32.1 %
	Surgery	96.1 %
	Chemotherapy	94.3 %
Current treatment	Yes	64.3 %
	No	35.0 %
	Unknown	0.7 %
Living situation	Not alone	81.7 %
	Alone	18.3 %
	Tablets for comorbidities	61.4 %
	Maintenance therapy	29.3 %




Results

Side effects of most concern



Results

Personal objectives to choose a maintenance therapy



Conclusion

- Ovarian cancer patients are willing to accept maintenance therapies for a longer time (tablets or IV)
- Only a few patients under maintenance therapy described their health status as bad
- Co-medication and age do not seem to negatively influence patients' preferences towards maintenance therapy
- There is a high need for more information and patient education regarding therapy goals and side effects of maintenance therapies

